Shares of NewLink Genetics Corp. (NASDAQ:NLNK) rose 2.9% on Tuesday . The company traded as high as $10.84 and last traded at $10.79, with a volume of 217,292 shares traded. The stock had previously closed at $10.49.

NLNK has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $62.00 price target on shares of NewLink Genetics Corp. in a research note on Friday, April 29th. Stifel Nicolaus reduced their price target on shares of NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, May 10th. Robert W. Baird reaffirmed an “outperform” rating and issued a $23.00 price target (down from $27.00) on shares of NewLink Genetics Corp. in a research note on Tuesday, May 10th. Mizuho reduced their price target on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 10th. Finally, SunTrust Banks Inc. lowered shares of NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $59.00 to $12.00 in a research note on Tuesday, May 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $23.29.

The firm’s market capitalization is $308.16 million. The company’s 50 day moving average is $10.92 and its 200-day moving average is $16.08.

NewLink Genetics Corp. (NASDAQ:NLNK) last announced its quarterly earnings data on Friday, July 29th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by $0.35. On average, equities research analysts predict that NewLink Genetics Corp. will post ($2.94) EPS for the current year.

Several large investors have recently made changes to their positions in NLNK. Dimensional Fund Advisors LP boosted its stake in shares of NewLink Genetics Corp. by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 48,507 shares of the company’s stock worth $1,765,000 after buying an additional 300 shares during the period. California State Teachers Retirement System boosted its stake in shares of NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock worth $1,402,000 after buying an additional 636 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock worth $1,993,000 after buying an additional 31,375 shares during the period. Finally, EQIS Capital Management boosted its stake in shares of NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock worth $1,515,000 after buying an additional 35,587 shares during the period.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.